1982 Volume 73 Issue 2 Pages 143-154
Basic studies and susceptibility testing of platina compounds was performed on a strain of human prostate cancer implanted into a nude mouse (Pro-1). The following results were obtained:
1) Subimplantation of the strain was successful in almost 100%, almost all are viable and no change was seen in the state of proliferation.
2) No hormone receptor of this strain was present, its susceptibility to estrogen is low and it was considered to have little hormone dependence.
3) The platina compound was directly administered into the abdominal cavities. There was no difference of susceptibility of platina compounds on the tumor proliferation curve noted between day 1 or next day after implantation, day 5 and day 9 on one hand and day 8, day 12 and day 16 in which new blood vessels developed on the other hand.
4) It was noted that repeated subimplantation did not change the susceptibility to anti-cancer drugs. We performed the susceptibility testing 1) based on the tumor proliferation curve, and 2) from the pathohistological appearance. Our conclusions are:
1) CDDP was effective in three doses, 5mg/kg, 2.5mg/kg and 1.25mg/kg.
2) 1-GHP was effective at 25mg/kg and 12.5mg/kg.
3) d-GHP was effective at 50mg/kg and 25mg/kg.
4) There was no effect seen with DBCP.
5) 1-OHP was effective only at 20mg/kg.
Regarding a safe therapeutic range, you can see that CDDP was safest and most effective, followed by d-GHP and 1-GHP. There was a close relationship noted between the pathohistological changes and the tumor proliferation curve.
